Valuation: Roche Holding AG

Capitalization 255B 326B 279B 242B 447B 31,247B 450B 3,042B 1,184B 14,828B 1,225B 1,199B 51,540B P/E ratio 2026 *
16.9x
P/E ratio 2027 * 15.8x
Enterprise value 266B 340B 290B 251B 466B 32,537B 468B 3,168B 1,233B 15,440B 1,276B 1,249B 53,668B EV / Sales 2026 *
4.24x
EV / Sales 2027 * 3.95x
Free-Float
88.75%
Yield 2026 *
3.13%
Yield 2027 * 3.21%
1 day-0.94%
1 week-2.05%
Current month-0.97%
1 month-0.60%
3 months-12.42%
6 months+8.76%
Current year-3.93%
1 week 313
Extreme 313
323.2
1 month 312
Extreme 312
326.7
Current year 291
Extreme 291
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
-0.94%-2.05%+21.74%+10.73% 326B
+2.61%+2.91%+36.15%+133.81% 906B
+2.75%+2.58%+55.23%+43.31% 555B
+0.31%+1.69%+10.90%+41.69% 368B
+0.13%+1.47%+35.23%+14.62% 289B
+0.78%+1.00%+29.63%+26.23% 285B
+0.96%-0.10%+48.05%-3.15% 280B
+0.91%+2.12%-31.78%-49.10% 208B
+0.05%+1.61%+24.40%+44.43% 182B
-1.40%-2.38%+31.17%+70.21% 165B
Average +0.39%+0.74%+26.07%+33.28% 356.36B
Weighted average by Cap. +0.60%+1.08%+30.74%+51.73%

Financials

2026 *2027 *
Net sales 62.75B 80.19B 68.48B 59.32B 110B 7,675B 110B 747B 291B 3,642B 301B 295B 12,659B 65.33B 83.5B 71.3B 61.76B 114B 7,991B 115B 778B 303B 3,792B 313B 307B 13,181B
Net income 14.79B 18.9B 16.14B 13.98B 25.89B 1,809B 26.03B 176B 68.56B 858B 70.93B 69.44B 2,984B 15.8B 20.2B 17.25B 14.94B 27.67B 1,933B 27.81B 188B 73.26B 917B 75.79B 74.2B 3,188B
Net Debt 10.54B 13.47B 11.51B 9.97B 18.46B 1,290B 18.55B 126B 48.88B 612B 50.56B 49.5B 2,127B 2.71B 3.47B 2.96B 2.57B 4.75B 332B 4.78B 32.32B 12.58B 158B 13.01B 12.74B 548B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
13/05/26 320.00 CHF -0.47% 611,255
12/05/26 321.50 CHF +0.66% 654,692
11/05/26 319.40 CHF +1.30% 724,136
08/05/26 315.30 CHF -0.94% 590,249
07/05/26 318.30 CHF -1.12% 690,846
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
320.00CHF
Average target price
360.76CHF
Spread / Average Target
+12.74%

Quarterly revenue - Rate of surprise